Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 22, 2005, Pages 5044-5051

  Leonard, John P ^a   Coleman, Morton ^a   Ketas, Jamie ^a   Ashe, Michelle ^a   Fiore, Jennifer M ^a   Furman, Richard R ^a   Niesvizky, Ruhen ^a   Shore, Tsiporah ^a   Chadburn, Amy ^a   Horne, Heather ^a   Kovacs, Jacqueline ^a   Ding, Cliff L ^a   Wegener, William A ^a   Horak, Ivan D ^a   Goldenberg, David M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPRATUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; HLL2 AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FLUSHING; FOLLICULAR LYMPHOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; LIMB PAIN; MALE; NAUSEA; NONHODGKIN LYMPHOMA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RIGOR; SCORING SYSTEM; SIDE EFFECT; TREATMENT RESPONSE; AGED; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 24644476583     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.13.821     Document Type: Article

References (45)

1. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
2. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004
3. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002
4. Siebert R, Rosenwald A, Staudt LM, et al: Molecular features of B-cell lymphoma. Curr Opin Oncol 13:316-324, 2001
5. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
6. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
7. Coiffier B, Salles G: Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma. Blood 104: 1584-1585, 2004
8. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
9. Fisher RI, Shah P: Current trends in large cell lymphoma. Leukemia 17:1948-1960, 2003
10. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
11. Dorken B, Moldenhauer G, Pezzutto A, et al: HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136:4470-4479, 1986
12. Leonard JP, Coleman M, Ketas JC, et al: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21:3051-3059, 2003
13. Leonard JP, Coleman M, Ketas JC, et al: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 10:5327-5334, 2004
14. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1990
15. Jaffe ES, Harris NL, Diebold J, et al: World Health Organization Classification of lymphomas: A work in progress. Ann Oncol 9:S25-S30, 1998 (suppl 5)
16. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
17. Kaplan EL: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481, 1958
18. Coiffier B, Haioun C, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927-1932, 1998
19. Hainsworth JD: Prolonging remission with rituximab maintenance therapy. Semin Oncol 31:17-21, 2004
20. Eisenbeis CF, Grainger A, Fischer B, et al: Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: A preclinical and phase I study. Clin Cancer Res 10:6101-6110, 2004
21. Gluck WL, Hurst D, Yuen A, et al: Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 10:2253-2264, 2004
22. Cheson BD: CHOP plus rituximab: Balancing facts and opinion. N Engl J Med 346:280-282, 2002
23. Czuczman MS: CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 26:88-96, 1999
24. Czuczman MS, Fallon A, Mohr A, et al: Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 29: 36-40, 2002
25. Czuczman MS, Weaver R, Alkuzweny B, et al: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711-4716, 2004
26. Teeling JL, French RR, Cragg MS, et al: Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104: 1793-1800, 2004
27. Stein R, Qu Z, Chen S, et al: Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 10:2868-2878. 2004
28. Nagajothi N, Matsui WH, Mukhina GL, et al: Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins. Leuk Lymphoma 45:795-799, 2004
29. Engel P, Nojima Y, Rothstein D, et al: The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol 150:4719-4732, 1993
30. Engel P. CD22. J Biol Regul Homeost Agents 14:295-298, 2000
31. Stein R, Belisle E, Hansen HJ, et al: Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother 37:293-298, 1993
32. 90Y-Epratuzumab): Do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44:2000-2018, 2003
33. Cesano A, Gayko U: CD22 as a target of passive immunotherapy. Semin Oncol 30:253-257, 2003
34. Siegel AB, Goldenberg DM, Cesano A, et al: CD22-directed monoclonal antibody therapy for lymphoma. Semin Oncol 30:457-464, 2003
35. Carnahan J, Wang P, Kendall R, et al: Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin Cancer Res 9:39825-39903, 2003
36. Maloney DG, Smith B, Rose A: Rituximab: Mechanism of action and resistance. Semin Oncol 29:2-9, 2002
37. Shih LB, Lu HH, Xuan H, et al: Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56:538-545, 1994
38. Furman RR, Coleman M, Leonard JP: Epratuzumab in non-Hodgkin's lymphomas. Curr Treat Options Oncol 5:283-288, 2004
39. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
40. Strauss SJ, Lister TA, Morschauser F, et al: Multi-center, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: Promising preliminary results. J Clin Oncol 23:577, 2004 (suppl; abstr 6579)
41. Emmanouilides C, Leonard JP, Schuster SJ, et al: Multi-center, phase 2 study of combination antibody therapy with epratuzumab plus rituximab in recurring low-grade NHL. Blood 102: 69a, 2003
42. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003
43. Coiffier B: New treatment strategies in lymphomas: Aggressive lymphomas. Ann Hematol 83:S73-S74, 2004 (suppl 1)
44. Leonard JP, Coleman M, Hainsworth JD, et al: Phase II study of oblimersen sodium (G3139) alone and with R-CHOP in mantle cell lymphoma (MCL). Proc Am Soc Clin Oncol 22: 566, 2003 (abstr 2276)
45. Micallef IN, Kahl BS, Gayko U, et al: Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 23:577, 2004 (suppl; abstr 6580)